ENXTPA:DBV

Stock Analysis Report

Executive Summary

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Share Price & News

How has DBV Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.7%

DBV

1.1%

FR Biotechs

-0.2%

FR Market


1 Year Return

-56.8%

DBV

-38.4%

FR Biotechs

2.7%

FR Market

DBV underperformed the Biotechs industry which returned -38.6% over the past year.

DBV underperformed the Market in France which returned 2.7% over the past year.


Share holder returns

DBVIndustryMarket
7 Day0.7%1.1%-0.2%
30 Day2.1%3.8%4.7%
90 Day17.9%-3.9%1.7%
1 Year-56.8%-56.8%-38.4%-38.4%6.2%2.7%
3 Year-73.7%-73.7%-56.8%-57.0%43.9%30.0%
5 Year-43.1%-43.1%-57.4%-58.2%62.1%38.3%

Price Volatility Vs. Market

How volatile is DBV Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DBV Technologies undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

DBV Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).

DBV Technologies's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

DBV Technologies is loss making, we can't compare its value to the FR Biotechs industry average.

DBV Technologies is loss making, we can't compare the value of its earnings to the France market.


Price Based on Expected Growth

Unable to calculate PEG ratio for DBV Technologies, we can't assess if its growth is good value.


Price Based on Value of Assets

DBV Technologies is overvalued based on assets compared to the FR Biotechs industry average.


Next Steps

Future Growth

How is DBV Technologies expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

53.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

DBV Technologies's revenue is expected to grow significantly at over 20% yearly.

DBV Technologies's earnings are expected to grow significantly at over 20% yearly.

DBV Technologies's revenue growth is expected to exceed the France market average.

DBV Technologies's earnings growth is expected to exceed the France market average.

DBV Technologies's earnings growth is expected to exceed the low risk savings rate of 0.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if DBV Technologies will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has DBV Technologies performed over the past 5 years?

-36.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

DBV Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare DBV Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare DBV Technologies's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if DBV Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if DBV Technologies has efficiently used its assets last year compared to the FR Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if DBV Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is DBV Technologies's financial position?


Financial Position Analysis

DBV Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

DBV Technologies's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

DBV Technologies's level of debt (1.4%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (4.9% vs 1.4% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 87.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

DBV Technologies has less than a year of cash runway based on current free cash flow.

DBV Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 32.3% each year.


Next Steps

Dividend

What is DBV Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate DBV Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate DBV Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as DBV Technologies has not reported any payouts.

Unable to verify if DBV Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as DBV Technologies has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of DBV Technologies's dividends in 3 years as they are not expected to pay a notable one for France.


Next Steps

Management

What is the CEO of DBV Technologies's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Daniel Tassé (59yo)

0.8yrs

Tenure

€4,142,530

Compensation

Mr. Daniel Tassé has been the Chief Executive Officer at DBV Technologies S.A. since November 29, 2018 and has been its Director since March 5, 2019. He served as the Chairman and Chief Executive Officer o ...


CEO Compensation Analysis

Daniel's remuneration is higher than average for companies of similar size in France.

Insufficient data for Daniel to compare compensation growth.


Management Age and Tenure

2.3yrs

Average Tenure

57yo

Average Age

The tenure for the DBV Technologies management team is about average.


Board Age and Tenure

0.5yrs

Average Tenure

64yo

Average Age

The average tenure for the DBV Technologies board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

Buy€14,999,99909 Apr 19
Bpifrance Participations SA
EntityCompany
Shares1,247,920
Max Price€12.02
Buy€1,950,77209 Apr 19
Icade
EntityCompany
Shares60,000
Max Price€34.15

Ownership Breakdown


Management Team

  • Pierre-Henri Benhamou (64yo)

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0.5yrs
    • Compensation: €6.59m
  • Hugh Sampson (70yo)

    Chief Scientific Officer & Member of Scientific Advisory Board

    • Tenure: 7.3yrs
  • Daniel Tassé (59yo)

    CEO & Director

    • Tenure: 0.8yrs
    • Compensation: €4.14m
  • Laurent Martin (52yo)

    Deputy Chief Executive Officer

    • Tenure: 4.3yrs
    • Compensation: €917.91k
  • Wence Agbotounou

    Chief Clinical Trial Officer & Senior VP

    • Tenure: 3.3yrs
  • Sara Sherman

    Senior Director of Investor Relations & Strategy

    • Tenure: 0yrs
  • Sébastien Robitaille (49yo)

    Chief of Staff & Interim Chief Financial Officer

    • Tenure: 0.08yrs
  • Joan Schmidt (55yo)

    Chief Legal Officer

    • Tenure: 1.3yrs
  • Joe Becker

    Vice President of Global Corporate Communications

    • Tenure: 0yrs
  • Caroline Daniere

    Chief Human Resources Officer

    • Tenure: 0.7yrs

Board Members

  • Claire Giraut (63yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: €153.10k
  • Michel de Rosen (68yo)

    Non-Executive Chairman

    • Tenure: 0.5yrs
    • Compensation: €130.00k
  • Pierre-Henri Benhamou (64yo)

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0.5yrs
    • Compensation: €6.59m
  • Torbjørn Bjerke (57yo)

    Independent Director

    • Tenure: 13.7yrs
    • Compensation: €153.10k
  • Hugh Sampson (70yo)

    Chief Scientific Officer & Member of Scientific Advisory Board

    • Tenure: 7.3yrs
  • Paul-Henri Lambert (80yo)

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Daniel Tassé (59yo)

    CEO & Director

    • Tenure: 0.8yrs
    • Compensation: €4.14m
  • Christophe Dupont

    Chairman of the Scientific Advisory Board

    • Tenure: 0yrs
  • Gideon Lack

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Robert Zeiger

    Member of the Scientific Advisory Board

    • Tenure: 0.3yrs

Company Information

DBV Technologies S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DBV Technologies S.A.
  • Ticker: DBV
  • Exchange: ENXTPA
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €638.897m
  • Shares outstanding: 36.12m
  • Website: https://www.dbv-technologies.com

Number of Employees


Location

  • DBV Technologies S.A.
  • 177-181 avenue Pierre Brossolette
  • Montrouge
  • Ile-de-France
  • 92120
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DBVENXTPA (Euronext Paris)YesCommon StockFREURMar 2012
DBVDB (Deutsche Boerse AG)YesCommon StockDEEURMar 2012
0QAJLSE (London Stock Exchange)YesCommon StockGBEURMar 2012
DBVPBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURMar 2012
DBVT.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2012
DBVTNasdaqGS (Nasdaq Global Select)SPON ADR EACH REPR ORDUSUSDOct 2014
DBVADB (Deutsche Boerse AG)SPON ADR EACH REPR ORDDEEUROct 2014

Biography

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunothe ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 21:19
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.